On 30 June 2026, the US Food and Drug Administration (FDA) allowed 20 ZYN nicotine pouch products to carry a health-risk claim for the first time. The claim says that using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. ZYN is the first nicotine pouch to receive this kind of order, and the decision has prompted a debate about what such claims actually tell people.
This article explains what the FDA decided, what the claim does and does not mean, and what it means for people who use nicotine.
What the FDA decided
The FDA issued modified risk granted orders to Swedish Match USA, Inc., a subsidiary of Philip Morris International, for 20 ZYN products. The orders cover ten flavours, including Cool Mint, Citrus, Coffee and Wintergreen, each available at 3 mg and 6 mg nicotine strength.
The FDA said the claim is scientifically accurate for these products, that consumers understand it, and that marketing the products with it would benefit the population as a whole. The order requires the company to run post-market surveillance and studies on how users behave and understand the risk information.
How ZYN got here
ZYN was first authorised for sale in the United States in January 2025, without any risk-reduction claim. That authorisation allowed the products to be sold, but the company could not tell consumers they were less harmful than cigarettes.
The FDA has continued to authorise new products. On 21 August 2026 it authorised 11 ZYN ULTRA products, and it said it had authorised 43 nicotine pouch products overall, 23 of them through a pilot programme.
What the claim means and does not mean
The claim is a comparison with cigarettes, not a statement that ZYN is safe. Three points matter here.
- It is relative. A lower risk than cigarettes is not the same as no risk. Nicotine is addictive. The FDA says that switching completely may reduce exposure to harmful chemicals for adults aged 21 and older who smoke or use smokeless tobacco.
- It applies only to specified products. The FDA says the order covers the named products, not nicotine pouches in general.
- It is not an FDA approval. The FDA states that the order does not mean it has “approved” the products. Companies cannot imply otherwise.
In its August 2026 authorisations, the FDA said the newer ZYN ULTRA products contain lower levels of most harmful and potentially harmful constituents than many other oral and smokeless tobacco products. Lower levels are not the same as none, and the long-term health effects of nicotine pouches are still being studied. The products have been on sale in the US for under two years, which is too short a time to measure the full effect on diseases such as cancer or heart disease.
The concern about young people
Researchers at the University of California, San Francisco, including Pamela Ling, director of the Center for Tobacco Control Research and Education, have argued that the claim gives the tobacco industry a powerful marketing tool. Their concern is that the claim could help attract a new generation of users, rather than only helping adults who smoke switch.
Whether the claim changes youth use is one of the questions the required post-market studies are meant to answer.
If you smoke
For someone who smokes, the most important step is to stop smoking completely. The FDA’s claim relates to switching from cigarettes entirely, and using a nicotine pouch alongside smoking does not carry the same benefit. Anyone who wants to quit can speak with a doctor or pharmacist about approved support options, which include medicines, behavioural programmes and quitline services.
If you do not smoke
Someone who does not use nicotine has no health reason to start because of this claim. The FDA order describes a benefit for people who would otherwise continue to smoke or use smokeless tobacco.
Frequently asked questions
Which ZYN products have the claim?
The FDA order covers 20 ZYN products in ten flavours, each in 3 mg and 6 mg strengths. The claim does not automatically extend to other products, including the later ZYN ULTRA authorisations.
Does the FDA approve ZYN as safe?
No. The FDA has said that the order does not mean it approved the products. It means the agency has judged that the specific claim is scientifically accurate and would benefit the population overall.
Are nicotine pouches safer than cigarettes?
The FDA’s order rests on its review of how these products compare with cigarettes and other tobacco products. Lower risk is not the same as no risk, and long-term data on nicotine pouches is still limited.
Can nicotine pouches help me quit smoking?
The FDA’s claim is about switching completely to a pouch, not about quitting. Anyone trying to stop smoking should speak with a doctor or pharmacist about the options that have been tested for that purpose.
Sources
- US Food and Drug Administration, “FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim,” 30 June 2026: fda.gov
- FDA, Modified Risk Granted Orders letter to Swedish Match USA, Inc., 30 June 2026: fda.gov
- FDA, “FDA Authorizes 11 New Nicotine Pouches,” 21 August 2026: fda.gov
- University of California, San Francisco, “FDA Clears Zyn: Will Nicotine Pouches Hook a New Generation?,” July 2026: ucsf.edu
This article is general information, not medical advice, and does not replace assessment by a qualified healthcare professional. For any symptom or health concern, consult a clinician. See the medical disclaimer.
